During the previous decades, the practice of cancer prevention and intervention has achieved much success at the population level. However, it has become obvious that such achievements at the individual levels have been highly variable and, perhaps, disappointing. Therefore, to significantly improve efficacy, the United States and the EuropeanUnion have set up priority programs on the development of precision population health and personalized medicine. The emphasis will require a paradigm shift in focusing these activities onto individuals instead of
Piero Portincasa, Emilio Molina-Molina, Gabriella Garruti and David Q.-H. Wang
The present paper is written in the context of the FOIE GRAS project, which received funding from the EuropeanUnion’s Horizon 2020 Research and Innovation programme under the Marie Skłodowska-Curie Grant Agreement No. 722619.
Conflict of interest None to declare
1 Portincasa P, Moschetta A, Palasciano G. Cholesterol gallstone disease. Lancet. 2006;368:230-9. 10.1016/S0140-6736(06)69044-2
Portincasa P Moschetta A Palasciano G. Cholesterol gallstone disease Lancet 2006 368 230 9
2 Shabanzadeh DM. Incidence of